Search Results

You are looking at 1 - 3 of 3 items for :

  • "molecular biology" x
  • By Author: Sheehan, Jason P. x
Clear All
Restricted access

Mohamed Elsharkawy, Zhiyuan Xu, David Schlesinger and Jason P. Sheehan

schwannoma tumors in the cerebellopontine angle: a structured approach and management guidelines . Skull Base 18 : 217 – 227 , 2008 41 Sughrue ME , Yeung AH , Rutkowski MJ , Cheung SW , Parsa AT : Molecular biology of familial and sporadic vestibular schwannomas: implications for novel therapeutics. A review . J Neurosurg 114 : 359 – 366 , 2009 42 Wallner KE , Pitts LH , Davis RL , Sheline GE : Radiation therapy for the treatment of non-eight nerve intracranial neurilemmoma . Int J Radiat Oncol Biol Phys 14 : 287 – 290 , 1988 43

Free access

Dale Ding, Robert M. Starke, John Hantzmon, Chun-Po Yen, Brian J. Williams and Jason P. Sheehan

understanding of the molecular biology of meningiomas and promoters of tumor progression may provide avenues for developing effective targeted agents or immunotherapies. 6 Currently, there are no chemotherapeutic regimens that effectively treat meningiomas, but agents such as bevacizumab are being evaluated for the treatment of Grade II and III meningiomas. 4 , 10 Finally, hypofractionated radiosurgery delivery systems, such as the Gamma Knife Extend (Elekta Instruments AB) may expand the versatility of radiosurgical treatment and ultimately result in better outcomes for

Restricted access

Zhiyuan Xu, Cheng-Chia Lee, Arjun Ramesh, Adam C. Mueller, David Schlesinger, Or Cohen-Inbar, Han-Hsun Shih and Jason P. Sheehan

surgical excision in terms of local tumor control, with a low risk of morbidity and almost no deaths. 28 Melanoma is the third most common primary tumor responsible for BM, and there is no Level 1 evidence regarding treatment once it has metastasized to the brain. 21 In clinical practice, multidisciplinary treatment options are used, including immunotherapy and small molecular inhibitors. Recent advancements in molecular biology have identified the BRAF mutation as a common mutation (approximately 50%) in melanoma. 11 BRAF mutation kinase inhibitors ( BRAF i